BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+4.49%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.36B
AUM Growth
+$9.36B
(-3%)
Cap. Flow
+$5.03M
Cap. Flow
% of AUM
0.05%
Top 10 Holdings %
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7
Top Buys
| 1 |
Insmed
INSM
|
$40.8M |
| 2 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$29.1M |
| 3 |
Candel Therapeutics
CADL
|
$25.9M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$20.8M |
| 5 |
CRISPR Therapeutics
CRSP
|
$18.3M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$192M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$17.6M |
| 3 |
Tango Therapeutics
TNGX
|
$5.78M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$5.31M |
| 5 |
Alector
ALEC
|
$4.32M |
Sector Composition
| 1 | Healthcare | 98.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roivant Sciences
ROIV
$8.6B
| $44.6M | 0.48% |
3,767,773
+969,057
| +35% | +$11.5M |
|
27
Sera Prognostics
SERA
$129M
| $44.2M | 0.47% |
5,434,399
| – | – |
|
28
Immunovant
IMVT
$2.91B
| $42.3M | 0.45% |
1,707,881
+482,471
| +39% | +$12M |
|
29
Xenon Pharmaceuticals
XENE
$2.99B
| $39M | 0.42% |
993,679
| – | – |
|
30
Celcuity
CELC
$2.3B
| $35.1M | 0.37% |
2,678,553
+803,575
| +43% | +$10.5M |
|
31
Monte Rosa Therapeutics
GLUE
$309M
| $34.1M | 0.36% |
4,916,095
| – | – |
|
32
Akero Therapeutics
AKRO
$3.65B
| $30.5M | 0.33% |
1,097,082
| – | – |
|
33
Cerus
CERS
$251M
| $30M | 0.32% |
19,477,339
| – | – |
|
|
GRAL
34
GRAIL, Inc. Common Stock
GRAL
$1.17B
| $29.1M | 0.31% |
+1,630,125
| New | +$29.1M |
|
35
IDEAYA Biosciences
IDYA
$2.26B
| $27.3M | 0.29% |
1,062,123
| – | – |
|
36
Krystal Biotech
KRYS
$4.35B
| $26.6M | 0.28% |
169,934
| – | – |
|
|
37
Candel Therapeutics
CADL
$281M
| $25.9M | 0.28% |
+2,981,983
| New | +$25.9M |
|
38
Praxis Precision Medicines
PRAX
$980M
| $25.5M | 0.27% |
331,533
+8,428
| +3% | +$649K |
|
|
IGMS
39
DELISTED
IGM Biosciences
IGMS
| $25M | 0.27% |
4,094,304
+1,994
| +0% | +$12.2K |
|
|
CNTA
40
Centessa Pharmaceuticals
CNTA
$2.13B
| $20.6M | 0.22% |
1,227,178
| – | – |
|
41
Merus
MRUS
$5.04B
| $18.9M | 0.2% |
450,000
+150,000
| +50% | +$6.31M |
|
42
Dyne Therapeutics
DYN
$1.92B
| $15.8M | 0.17% |
672,096
| – | – |
|
43
Neurogene
NGNE
$284M
| $15.4M | 0.16% |
674,450
+218,435
| +48% | +$4.99M |
|
44
Xencor
XNCR
$594M
| $15.4M | 0.16% |
670,431
| – | – |
|
|
BCAX
45
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $14.5M | 0.16% |
833,333
| – | – |
|
46
Prelude Therapeutics
PRLD
$69.1M
| $12.9M | 0.14% |
10,123,824
| – | – |
|
47
Ionis Pharmaceuticals
IONS
$9.64B
| $12.5M | 0.13% |
357,915
+134,445
| +60% | +$4.7M |
|
|
ALMS
48
Alumis Inc. Common Stock
ALMS
$483M
| $12.3M | 0.13% |
1,562,500
| – | – |
|
49
Neumora Therapeutics
NMRA
$283M
| $11M | 0.12% |
1,034,600
| – | – |
|
50
Design Therapeutics
DSGN
$339M
| $10.8M | 0.11% |
1,743,725
| – | – |
|